In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center ...
Mar 8, 2015
0
9
A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's ...
Mar 7, 2015
0
8
(HealthDay)—Women who survive breast cancer may have a higher-than-average risk of developing thyroid cancer in the next several years, a new study suggests.
Mar 6, 2015
0
48
After five years of follow-up, a majority of asymptomatic, benign thyroid nodules exhibited no significant change in size, or actually decreased in size, and diagnoses of thyroid cancer were rare, according to a study in ...
Mar 3, 2015
0
7
Cancer researchers at Mayo Clinic's campus in Jacksonville, Florida, have identified a molecule they say is important to survival of anaplastic thyroid carcinoma (ATC)—a lethal tumor with no effective therapies. The molecule ...
Feb 17, 2015
0
10
(HealthDay)—Lenvima (lenvatinib) has been approved by the U.S. Food and Drug Administration to treat differentiated thyroid cancer (DTC) that has progressed despite radioactive iodine therapy, the agency said Friday in ...
Feb 13, 2015
0
3
In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with ...
Feb 11, 2015
0
2
For the first time, researchers have found that exposure to radioactive iodine is associated with more aggressive forms of thyroid cancer, according to a careful study of nearly 12,000 people in Belarus who were exposed when ...
Oct 28, 2014
0
1
A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas Research Network has identified markers of aggressive tumors, which could allow for better targeting of appropriate treatments to individual patients.
Oct 23, 2014
0
0
The DNA of a woman whose lethal thyroid cancer unexpectedly "melted away" for 18 months has revealed new mechanisms of cancer response and resistance to the drug everolimus, said researchers from Dana-Farber Cancer Institute ...
Oct 8, 2014
0
0
